

NCI's Clinical Trials Cooperative Groups National Meetings Report

Winter 2009

In This Issue

ACRIN Fall, ASCO Breast Cancer Symposium, ASH, ASTRO, EORTC-NCI-AACR Symposium on Molecular Targets & Cancer Therapeutics, ESTRO27, ISOQOL, SABCS, SIOP, SNO, & Others

Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Leukemia, Myelodysplasia, and Transplantation](#)
- [Lung Cancer](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD and DCP Activities](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

NSABP-B-30: The National Surgical Adjuvant Breast and Bowel Project (NSABP), in NSABP-B-30 found that 4 cycles of concurrent TAC was inferior to sequential AC-T for overall survival and disease-free survival. "This result, combined with the results from the Eiermann study, has huge implications for the length of treatment with this regimen," said NSABP B-30 principal investigator Sandra Swain, MD, from the Washington Cancer Institute, in Washington, DC. "If you are going to use TAC, use 6 cycles," she summarized. The NSABP B30 study is important. Giving TAC for 4 cycles was part of the experimental nature of this study, and these results indicate once again that duration matters within the context of each regimen we use. (*Breast Cancer/NSABP/Swain et al.*)

POG-9906: COG researchers collaborated with researchers from St. Jude Children's Research Hospital, the University of New Mexico, and NCI as part of the Childhood Cancer TARGET Initiative to discover that the Ikaros gene (IKZF1) is altered in approximately 25% of children with high-risk ALL and is a highly significant independent predictor of poor outcome. The gene expression signature of IKZF1-mutated BCR-ABL1 negative ALL is closely related to that of BCR-ABL1 positive ALL, an observation with potential therapeutic significance. (*Leukemia, Myelodysplasia, and Transplantation/COG/Mullighan et al.*)



Cooperative Group Abstracts

Breast Cancer

ACRIN

Berg W: Reasons for Refusing a Screening Breast MRI in a Population of Women at Elevated Risk of Breast Cancer: ACRIN 6666. Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6666

Hylton N: MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy; Preliminary Findings of ACRIN 6657. American College of Radiology Imaging Network (ACRIN) Fall, Arlington, Virginia, Oct, 2008.

Protocol(s): ACRIN-6657

Hylton NM, Blume J, Bernreuter W, Pisano E, Rosen M, Morris E, Weatherall P, Lehman C, Polin S, Newstead G, Marques H, Schnall M, Esserman LJ: MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657. Radiological Society of North America, Chicago, Illinois, Nov, 2008. Abst. SSA01-01.

http://rsna2008.rsna.org/event_display.cfm?em_id=6006524&killterms=Y

Protocol(s): ACRIN-6657, CALGB-150007

Pisano E: Radiologist Analysis of ACRIN Digital Mammographic Imaging Screening Trial (DMIST) Cancer Cases - A Logistic Regression Model. Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6652

CALGB

Livasy C, Carey L, DiMichelle A, Cowan D, Little D, Markey J, Moore D, Dressler L: Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 5102.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_478&terms=

Protocol(s): ACRIN-6657, CALGB-150007

ECOG

Badve S, Baehner FL, Gray R, Childs B, Maddala T, Liu M, Rowley S, Davidson N, Shak S, Goldstein LJ, Sledge GW, Sparano JA: Comparison of ER and PR Assessment by Local IHC, Central IHC, and Central Quantitative RT-PCR in ECOG Breast Cancer Study 2197. ASCO Breast Cancer Symposium, Washington, DC, Sep, 2008. Abst. 44.

http://www.oncotypedx.com/PDFs/dda1aUSCAP2008_Abstract_44.doc

Protocol(s): E2197

Baehner FL, Gray R, Childs B, Maddala T, Rowley S, Shak S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA, Badve S: HER2 concordance between central laboratory immunohistochemistry & quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197. ASCO Breast Cancer Symposium, Washington, DC, Sep, 2008. Abst. 13.

http://www.oncotypedx.com/PDFs/6c1c4ASCO_Breast_2008Meeting_Abstract_13.pdf

Protocol(s): E2197

Baehner FL, Goldstein LJ, Gray R, Maddala T, Shak S, Sledge GW, Sparano JA, Badve S: Analysis of Revised Nottingham Tumor Grade Constitutive Components and Recurrence Free Interval in ECOG Breast Cancer Study E2197. ASCO Breast Cancer Symposium, Washington, DC, Sep, 2008. Abst. 82.

http://www.oncotypedx.com/PDFs/dc227USCAP2008_Abstract_82.doc

Protocol(s): E2197

Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL, Perez EA, Shulman LN, Martino S, Sledge Jr. GW, Davidson NE: GRB7-Dependent Pathways are Potential Therapeutic Targets in Triple-Negative Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 25.

http://www.oncotypedx.com/PDFs/Abstract_25.pdf

Protocol(s): E2197

NCCTG

Perez EA, Reinholz MM, Dueck AC, Wiktor AE, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Jenkins RB: c-MYC Amplification and Correlation with Patient Outcome in Early Stage HER2+ Breast Cancer from the NCCTG Adjuvant Intergroup Trial N9831. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 56.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_822&terms=

Protocol(s): N9831

NCIC Clinical Trials Group

Moy B, Tu D, Shepherd LE, Palmer MJ, Ingle JN, Goss PE: NCIC CTG MA.17: Hormone Receptor Expression of In-Breast Recurrences and Contralateral Primary Breast Cancers Arising on Aromatase Inhibitors. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 1134.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_572&terms=

Protocol(s): JMA17

NSABP

Ganz PA, Land SR, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG III, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM: NSABP B-30: Definitive Analysis of Quality of Life (QOL) and Menstrual History (MH) Outcomes from a Randomized Trial Evaluating Different Schedules and Combinations of Adjuvant Therapy Containing Doxorubicin, Docetaxel, and Cyclophosphamide in Women with Operable, Node-Positive Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 76.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_852&terms=

Protocol(s): NSABP-B-30

Legault C, Resnick S, Hogan P, Maki P, Coker C, Bevers TB, Shumaker S: Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR). International Conference on Alzheimer's Disease, Chicago, Illinois, Jul, 2008. Abst. 1961.

Protocol(s): NSABP-P-2

Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Hortobagyi GN, Paik S, Symmans WF: Evaluation of Microtubule Associated Protein Tau Expression as Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 54.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_505&terms=

Protocol(s): NSABP-B-28

Swain SM, Jeong J-H, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Ganz PA, Land SR: NSABP B-30: Definitive Analysis of Patient Outcome from a Randomized Trial Evaluating Different Schedules and Combinations of Adjuvant Therapy Containing Doxorubicin, Docetaxel and Cyclophosphamide in Women with Operable, Node-Positive Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 75.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_1017

Protocol(s): NSABP-B-30

RTOG

Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe SJ, Arthur D, Petersen I, White J, McCormick B. Initial Efficacy Results of RTOG 0319: Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I/ II Breast Carcinoma. Int J Radiat Oncol Biol Phys 2008; 72(Suppl):Abst. 6.

[http://www.redjournal.org/article/S0360-3016\(08\)00990-5/fulltext](http://www.redjournal.org/article/S0360-3016(08)00990-5/fulltext)

Protocol(s): RTOG-0319

SWOG

Rimm DL, Barlow WE, Harigopal M, Tedeschi G, Peggy PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Hayes DF: Multiplexed AQUA-Based Assessment of SWOG 9313 Shows Prognostic Value of Continuous ER, PR and HER2 Assessment. San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, Dec, 2008. Abst. 704.

http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_747

Protocol(s): S9313A, INT-0137, S9313A-ICSC

CNS Cancer

COG

Malogolowkin M, London W, Frazier AL, Olson TA: Brain Metastases in Children with high risk Germ Cell Tumors (GCT): a report from the Children's Oncology Group (COG). International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. C004.

Protocol(s): INT-0097, INT-0106

RTOG

Bae K, Bruner DW, Yan Y, Coyne J, Movsas B: Patterns of Missing Mini Mental Status Exam Data in Radiation Therapy Oncology Group (RTOG) Brain Tumor Trials. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 2736.

[http://www.redjournal.org/article/S0360-3016\(08\)01956-1/fulltext](http://www.redjournal.org/article/S0360-3016(08)01956-1/fulltext)

Protocol(s): Multiple Trials

Brachman DG, Ashby LS, Wang M, Thomas T, Stea B, Mehta M: Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma: Results of RTOG 0513 Phase I Dose Escalation Toxicity Analysis.

Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008.

Protocol(s): RTOG-0513

Cairncross G, Wang M, Chang S, Shaw E, Jenkins R, Scheithauer B, Buckner J, Fink K, Mehta M, Curran W: Randomized Trial of Chemotherapy Plus Radiotherapy (RT) versus RT alone for Anaplastic Oligodendroglioma (RTOG 9402): The Perspective of Longer Follow-up. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 16.

[http://www.redjournal.org/article/S0360-3016\(08\)01000-6/fulltext](http://www.redjournal.org/article/S0360-3016(08)01000-6/fulltext)

Protocol(s): INT-0149, RTOG-94-02

Other Participating Group(s): ECOG, EORTC, NCCTG, NCIC, SWOG

Chakravarti A, Wang M, Mischel P, Robins I, Guha A, Machtay M, Curran W, Roach M, Mehta M, Dicker A: An Update On Correlative Molecular Endpoints From RTOG 0211: Phase I/II Study Of Gefitinib + Radiation For Newly Diagnosed Glioblastoma (GBM). Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008. Abst. ET-12.

Protocol(s): RTOG-0211

Chakravarti A, Wang M, Mischel P, Robins I, Guha A, Machtay M, Curran W, Roach M, Mehta M, Dicker A: An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 20.

[http://www.redjournal.org/article/S0360-3016\(08\)01004-3/fulltext](http://www.redjournal.org/article/S0360-3016(08)01004-3/fulltext)

Protocol(s): RTOG-0211

Chang S, Wang M, Cairncross G, Gilbert M, Bahary J-P, Dolinskas C, Aldape K, Chakravarti A, Curran Jr W, Schiff D, Jaeckle K, Barger G, Werner-Wasik M, Brachman DG, Komaki R, Patel R, Mehta M: Toxicity Results of RTOG 9813—A Phase III Randomized Study of Radiation Therapy (RT) and Temozolomide (TMZ) versus RT and Nitrosourea (NU) for Anaplastic Astrocytoma (AA) and Mixed Anaplastic Oligoastrocytoma (MAOA). Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008.

Protocol(s): RTOG-98-13

Other Participating Group(s): ECOG, NCCTG, SWOG

Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang H-Z, Hammond E, Curran Jr. W, Mehta MP: The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 2083.

[http://www.redjournal.org/article/S0360-3016\(08\)02577-7/fulltext](http://www.redjournal.org/article/S0360-3016(08)02577-7/fulltext)

Protocol(s): Multiple Trials

Choucair AK, Moughan J, Ford CD, Hansen J, Schultz CJ, Schulsinger A, Hammond EH, Mehta MP, Curran Jr WJ: Predictive Value of hMLH1 after Adjusting for RPA Class in Patients with GBMs Treated on RTOG Protocols. Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008.

Protocol(s): Multiple Trials

Lassman AB, Wang M, Gilbert MR, Aldape K, Wagner H, Brachman DG, Malkin MG, Pajak T, Mehta M: Phase 2 Trial of Dasatinib in Patients with Recurrent Glioblastoma (RTOG 0627). Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008.

Protocol(s): RTOG-0627

Shaw EG, Wang M, Coons S, Brachman D, Buckner J, Stelzer K, Barger G, Brown P, Gilbert M, Mehta M: Long-Term Results of Radiation Therapy Oncology Group (RTOG) Protocol 9802: Radiation Therapy (RT) versus RT + Procarbazine, CCNU and Vincristine (PCV) Chemotherapy for Adult Low-Grade Glioma (LGG). Society for Neuro Oncology (SNO), Las Vegas, Nevada, Nov, 2008. Abst. RO-10.

Protocol(s): RTOG-98-02

Other Participating Group(s): ECOG, NCCTG, SWOG

Gastrointestinal Cancer

ACRIN

Blevins M: National CT Colonography Trial (ACRIN 6664): Are CT Colonography, Colonoscopy and Pathology Giving the Same Measures for Polyp Size? Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6664

Fletcher J, Herman B, Chen MH, Johnson CD: ACRIN 6664: Living on the High Plateau—Can Training and Testing Be Used to Ensure High Performance at CT Colonography? Radiological Society of North America, Chicago, Illinois, Nov, 2008. Abst. SSA06-08.

http://rsna2008.rsna.org/event_display.cfm?em_id=6012820

Protocol(s): ACRIN-6664

Hara A: National CT Colonography Trial (ACRIN 6664): Agree to Disagree: Do Reader Preferences Affect Performance at CTC? Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6664

Herman B: Can Training and Testing be Used to Ensure High Performance? Results of the ACRIN 6664 Reader Training. American College of Radiology Imaging Network (ACRIN) Fall, Arlington, Virginia, Oct, 2008.

Protocol(s): ACRIN-6664

Kuo M: National CT Colonography Trial (ACRIN 6664): The Pursuit of Cleanliness: Effect of Preparation Type on Exam Quality and/or Performance at CTC? Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6664

RTOG

Farrell J, Bae K, Fromm M, Regine W, Abrams R, Safran H, Hoffman J, Benson A, MacDonald J, Dicker A, Elsaleh H: Validation of Randomization Based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 31.

[http://www.redjournal.org/article/S0360-3016\(08\)01015-8/fulltext](http://www.redjournal.org/article/S0360-3016(08)01015-8/fulltext)

Protocol(s): RTOG-97-04

Other Participating Group(s): ECOG, SWOG

Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C: 5-Year Results of RTOG-0012 Randomized Phase II Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 2164.

[http://www.redjournal.org/article/S0360-3016\(08\)01482-X/fulltext](http://www.redjournal.org/article/S0360-3016(08)01482-X/fulltext)

Protocol(s): RTOG-R-0012

Myerson R, Garofalo M, el Naqa I, Abrams R, Bosch W, Das P, Gunderson L, Hong T, Kim J, Willett CG, Kachnic LA: Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 156.

[http://www.redjournal.org/article/S0360-3016\(08\)01143-7/fulltext](http://www.redjournal.org/article/S0360-3016(08)01143-7/fulltext)

Protocol(s): Multiple Trials

Showalter TN, Winter K, Berger AC, Regine WF, Abrams R, Safran H, Hoffman J, Benson AB, MacDonald JS, Willett CG: Total Nodes Examined (TNE) and Number of Positive Nodes (NPN) Predict Survival in Patients Undergoing Pancreaticoduodenectomy (PD) Followed by Adjuvant Chemoradiation (CRT) for Pancreatic Cancer—A Secondary Analysis of RTOG 9704. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 29.

[http://www.redjournal.org/article/S0360-3016\(08\)01013-4/fulltext](http://www.redjournal.org/article/S0360-3016(08)01013-4/fulltext)

Protocol(s): RTOG-97-04

Other Participating Group(s): ECOG, SWOG

SWOG

Smalley SR, Rankin C, Benedetti J, Williamson SK, Robertson JM, Tyvin R, Martenson JA, Benson AB, Mayer RJ, Cripps C: Pelvic Failure Analysis in INT 0144: Evaluation of Chemotherapy Regimen, Risk Group Stratification, and Nodal Count. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 154.

[http://www.redjournal.org/article/S0360-3016\(08\)01141-3/fulltext](http://www.redjournal.org/article/S0360-3016(08)01141-3/fulltext)

Protocol(s): INT-0144, SWOG-9304A-ICSC

Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC, RTOG

Genitourinary Cancer

RTOG

Hsu I-C, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H: Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 1045.

[http://www.redjournal.org/article/S0360-3016\(08\)01282-0/fulltext](http://www.redjournal.org/article/S0360-3016(08)01282-0/fulltext)

Protocol(s): RTOG-0321

Khor L-Y, Bae K, Al-Saleem T, Hammond ME, Fisher B, Byhardt R, Asbell S, Shipley W, Sandler H, Pollack A: Protein Kinase A RI-a Overexpression is Associated with Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy: A Secondary Analysis of RTOG 92-02. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 119.

[http://www.redjournal.org/article/S0360-3016\(08\)01105-X/fulltext](http://www.redjournal.org/article/S0360-3016(08)01105-X/fulltext)

Protocol(s): RTOG-92-02

Pollack A, Bae K, Khor L, Hammond EH, Chakravarti A, Dicker A, Brereton HD, Byhardt R, Venketesan V, Sandler H: A Model for Distant Metastasis Incorporating Tissue Biomarkers from Prostate Cancer Patients in Radiation Therapy Oncology Group (RTOG) 92-02. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 126.

[http://www.redjournal.org/article/S0360-3016\(08\)01112-7/fulltext](http://www.redjournal.org/article/S0360-3016(08)01112-7/fulltext)

Protocol(s): RTOG-92-02

SWOG

Lerner SP, Stein JP, Stadler WM, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R: Results of the p53 Targeted Therapy trial for patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urological Oncology, Bethesda, Maryland, Dec, 2008.

Protocol(s): SWOG-4B951

Swanson G, Thompson I, Tangen C, Pardelo J, Canby-Hagino E, Crawford E, Miller G, Lucia M, Forman J, Chin J, Messing E: Updated Results of SWOG 8794: Adjuvant Radiation for High Risk Prostate Cancer. *Radiotherapy & Oncology* 2008; 88 (S2)(2008):Abst. 449.

<http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf>

Protocol(s): INT-0086

Swanson G, Thompson IM, Tangen C, Paradelo J, Canby-Hagino E, Crawford E, Miller G, Lucia MS, Forman J, Chin J: Update of SWOG 8794: Adjuvant Radiotherapy for pT3 Prostate Cancer Improves Metastasis Free Survival. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 66.

[http://www.redjournal.org/article/S0360-3016\(08\)01051-1/fulltext](http://www.redjournal.org/article/S0360-3016(08)01051-1/fulltext)

Protocol(s): INT-0086

Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC, RTOG

Thompson I, Goldman B, Tangen C, Swanson G, Chin J, Messing E, Canby-Hagino E, Forman J, Crawford E: Prognostic Significance of Pathologic SV Involvement and the Effect of Adjuvant Radiation Therapy on Outcome. *Radiotherapy & Oncology* 2008; 88 (S2)(2008):Abst. 1057.
<http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf>
 Protocol(s): INT-0086

Gynecologic Cancer

GOG

DiSaia PJ, Blessing JA, Reese L, Ramiez N, Creasman WT, Brinton LA, Darcy KM, Lankes HA, Sucheston L, McMeekin DS, Miller DS, Birrer MJ: GOG#210: A Molecular Staging Study of Endometrial Cancer -- A Cooperative Group-Initiated Resource to Facilitate Translational Research. NCI Translational Science Meeting, Washington, DC, Nov, 2008. Abst. 298.
http://ncitranslates.nci.nih.gov/docs/abstract_book.pdf
 Protocol(s): GOG-0210

Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro PA: Results from a Phase II Trial of Ixabepilone for Women with Advanced or Recurrent Endometrial Cancer. International Gynecologic Cancer Society (Biennial Meeting), Bangkok, Thailand, Oct, 2008. Abst. 81.
http://www.igcs.org/Abstract/meeting_2008_81.html
 Protocol(s): GOG-0129P

RTOG

Doll C, Winter K, Gaffney D, Ryu J, Jhingran A, Dicker A, Weidhaas J, Miller B, Magliocco A: ERCC1, COX-2, and p53 Expression in Patients with Locally Advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG 0128. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 2415.
[http://www.redjournal.org/article/S0360-3016\(08\)01023-7/fulltext](http://www.redjournal.org/article/S0360-3016(08)01023-7/fulltext)
 Protocol(s): RTOG-C-0128

Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, Souhami L, Small W, Berk L, Gaffney D: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvic for Post-operative Patients with Endometrial Carcinoma (RTOG 0418). *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 35.
[http://www.redjournal.org/article/S0360-3016\(08\)01019-5/fulltext](http://www.redjournal.org/article/S0360-3016(08)01019-5/fulltext)
 Protocol(s): RTOG-0418

Weidhaas J, Li S, Winter K, Ryu J, Jhingran A, Miller B, Dicker A, Gaffney D: Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 34.
[http://www.redjournal.org/article/S0360-3016\(08\)01018-3/fulltext](http://www.redjournal.org/article/S0360-3016(08)01018-3/fulltext)
 Protocol(s): RTOG-C-0128

Head and Neck Cancer

RTOG

Eisbruch A, Harris J, Garden A, Chao C, Straube W, Harari P, Sanguineti G, Jones C, Bosch W, Ang K: Multi-Institutional Trial of IMRT for Early Oropharyngeal Cancer: Acceleration via Simultaneously Incorporated Boost (SIB) (RTOG 00-22). *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 219.

[http://www.redjournal.org/article/S0360-3016\(08\)01207-8/fulltext](http://www.redjournal.org/article/S0360-3016(08)01207-8/fulltext)

Protocol(s): RTOG-0022

Khuntia D, Harris J, Bentzen SM, Kies MS, Myers JN, Foote RL, Machtay M, Straube WL, Ang KK, Harari PM: Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 70.

[http://www.redjournal.org/article/S0360-3016\(08\)01055-9/fulltext](http://www.redjournal.org/article/S0360-3016(08)01055-9/fulltext)

Protocol(s): RTOG-0234

Le Q-T, Harris J, Magliocco T, Kong C, Diaz R, Trotti A, Erler JT, Dicker A, Amato GJ, Ang KK: Validation of Lysyl Oxidase (LOX) as a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma (HNSCC): Radiation Therapy Oncology Group (RTOG) Trial 9003. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, Hollywood, Florida, Oct, 2008. Abst. 102.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=60&abstractID=50177

Protocol(s): RTOG-90-03

Lee N, Harris J, Garden AS, Straube W, Bosch W, Morrison WH, Quivey J, Thorstadt W, Jones C, Ang K: Phase II Multi-institutional Study of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal (NPC) Carcinoma: Preliminary Clinical Results of RTOG 0225. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 217.

[http://www.redjournal.org/article/S0360-3016\(08\)01205-4/fulltext](http://www.redjournal.org/article/S0360-3016(08)01205-4/fulltext)

Protocol(s): RTOG-0225

Leukemia, Myelodysplasia, and Transplantation

COG

Arico M, Schrappe M, Hunger S, Carroll WL, Conter V, Di Lorenzo P, Manabe A, Saha V, Baruchel A, Vettenranta K, Tsuchida M, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui C, Valsecchi MG: Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. *Blood* 2008; 112(11):Abst. 568.

<http://ash.confex.com/ash/2008/webprogram/Paper3521.html>

Protocol(s): Multiple Trials

Bhatia S, Villaluna D, Landier W, Schaible AN, Hageman L, Hanby C, Leisenring WM, Hunger S, Robison L, Relling MV, Wong L: Prevalence and Predictors of Non-Adherence to 6-Mercaptopurine (6MP) in Children with Acute Lymphoblastic Leukemia (ALL) - a Children's Oncology Group Study. *Blood* 2008; 112(11):Abst. 897.

<http://ash.confex.com/ash/2008/webprogram/Paper2053.html>

Protocol(s): AALL03N1

Bhojwani D, Wang J, Yang J, Morrison D, Devidas M, Raetz E, Hunger S, Relling MV, Carroll WL: Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse. *Blood* 2008; 112(11):Abst. 3345.

<http://ash.confex.com/ash/2008/webprogram/Paper12384.html>

Protocol(s): Multiple Trials

Brown P, Alonzo T, Gerbing R, McIntyre E, Stirewalt DL, Lange B, Radich JP, Small D, Meshinchi S: High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children's Oncology Group Study. *Blood* 2008; 112(11):Abst. 147.

<http://ash.confex.com/ash/2008/webprogram/Paper7284.html>

Protocol(s): CCG-2961, CCG-2941

Czuchlewski DR, Harvey RC, Chen I, Bourguet-Vincent A, Rodgers BM, Vestal R, Ar K, Kang H, Wilson CS, Larsen EC, Hunger S, Loh M, Devidas M, Raetz E, Reaman GH, Carroll WL, Winick N, Willman CL: Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's On. *Blood* 2008; 112(11):Abst. 1514.

<http://ash.confex.com/ash/2008/webprogram/Paper7343.html>

Protocol(s): POG-9906

Franklin J, Alonzo T, Hurwitz C, Gerbing R, Smith FO, Arceci R, Feusner J, Mathew P, Iannone R, Meshinchi S, Lavey R, Wallace JD, Anderson KD, Winter LL, Glick K, Hirsch B, Raimondi SC, Gamis A: COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML): a report from the Children's Oncology Group. *Blood* 2008; 112(11):Abst. 136.

<http://ash.confex.com/ash/2008/webprogram/Paper11540.html>

Protocol(s): AAML03P1

Freyer DR, Seibel N, La MK, Devidas M, Carroll WL, Hunger S, Gaynon PS: Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents is Independent of Prior Treatment Intensity: A Report from the Children's Oncology Group (COG). *Blood* 2008; 112(11):Abst. 917.

<http://ash.confex.com/ash/2008/webprogram/Paper13841.html>

Protocol(s): CCG-1961

Gaikwad A, Rye CL, Devidas M, Izraeli S, Plon SE, Basso G, Pession A, Rabin K: Prevalence and Clinical Correlates of JAK2 Mutations in Pediatric Down Syndrome Acute Lymphoblastic Leukemia. *Blood* 2008; 112(11):Abst. 1506.

<http://ash.confex.com/ash/2008/webprogram/Paper6310.html>

Protocol(s): Multiple Trials

Gutierrez A, Sanda T, Winter SS, Larson RS, Silverman LB, Hunger S, Sallan SE, Look AT: LEF1 is a Tumor Suppressor in T Cell Acute Lymphoblastic Leukemia. Blood 2008; 112(11):Abst. 3802.
<http://ash.confex.com/ash/2008/webprogram/Paper13076.html>
 Protocol(s): POG-9404

Harvey RC, Chen I, Ar K, Hunger S, Loh M, Larsen EC, Devidas M, Raetz E, Reaman GH, Carroll WL, Winick N, Smith M, Dobbin K, Willman CL: Identification of Novel Cluster Groups in High-Risk Pediatric B-precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. A Children's Oncology Group (COG) Study. Blood 2008; 112(11):Abst. 2256.
<http://ash.confex.com/ash/2008/webprogram/Paper8825.html>
 Protocol(s): POG-9906, AALL0232

Ho PA, Alonzo T, Gerbing R, Pollard JA, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin J, Radich JP, Meshinchi S: CEBPA Mutations Predict Favorable Prognosis in Pediatric AML. Blood 2008; 112(11):Abst. 142.
<http://ash.confex.com/ash/2008/webprogram/Paper14451.html>
 Protocol(s): Multiple Trials

Hunger S, Devidas M, Camitta BM, Gaynon PS, Winick N, Reaman GH, Carroll WL: Improved Survival for Children with Acute Lymphoblastic Leukemia (ALL) from 1990-2005: A Report from the Children's Oncology Group (COG). International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. O.048.
 Protocol(s): Multiple Trials

Johnston DL, Alonzo T, Gerbing R, Lange B, Woods WG: Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome. Blood 2008; 112(11):Abst. 920.
<http://ash.confex.com/ash/2008/webprogram/Paper3426.html>
 Protocol(s): CCG-2891, CCG-2961, CCG-2861, CCG-2941

Lange B, Yang RK, Gan JJ, Hank JA, Sievers E, Alonzo T, Gerbing R, Sondel P: Clinical and serologic Interleukin-2 Receptor Alpha response to Interleukin-2 in CCG-CCG-2961, a randomized Phase III trial for pediatric Acute Myeloid Leukemia. Blood 2008; 112(11):Abst. 959.
<http://ash.confex.com/ash/2008/webprogram/Paper3842.html>
 Protocol(s): CCG-2961

Matloub YH, Bostrom BC, Hunger S, Angiolillo A, Cole C, Thomson B, Devidas M, Heerema NA, La MK, Buckley PJ, Carroll WL, Winick N, Sather H, Nachman J, Gaynon PS: Escalating Dose Intravenous Methotrexate without Leucovorin Rescue During Interim Maintenance is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study CCG-1991. Blood 2008; 112(11):Abst. 9.
<http://ash.confex.com/ash/2008/webprogram/Paper6498.html>
 Protocol(s): CCG-1991

Matloub YH, Gaynon PS, Jayabose S, Bostrom BC, Hunger S, Angiolillo A, Devidas M, Linda SB, Carroll WL, Winick N, Sather H, Pine SR: Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children's Oncology Group Study CCG-1991. *Blood* 2008; 112(11):Abst. 701.

<http://ash.confex.com/ash/2008/webprogram/Paper11308.html>

Protocol(s): CCG-1991

Mattano, Jr. LA, Nachman J, Devidas M, Winick N, Raetz E, Carroll WL, Whitlock J, Hunger S, Larsen EC: Increased incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): a report from the Children's Oncology Group (COG). *Blood* 2008; 112(11):Abst. 898.

<http://ash.confex.com/ash/2008/webprogram/Paper2380.html>

Protocol(s): AALL0232

Messinger Y, Higgins RR, Devidas M, Hunger S, Carroll AJ, Heerema NA: Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children's Oncology Group (COG) Study. *Blood* 2008; 112(11):Abst. 1477.

<http://ash.confex.com/ash/2008/webprogram/Paper1966.html>

Protocol(s): Multiple Trials

Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Harvey RC, Chen I, Clifford R, Carroll WL, Reaman GH, Devidas M, Gerhard D, Yang W, Bowman WP, Shurtleff SA, Relling MV, Smith M, Hunger S, Willman CL, Downing JR: Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia. *Blood* 2008; 112(11):Abst. 427.

<http://ash.confex.com/ash/2008/webprogram/Paper6057.html>

Protocol(s): POG-9906

Pollard JA, Alonzo T, Gerbing R, Raimondi SC, Hirsch B, Franklin J, Gamis A, Loken MR, Meshinchi S: Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML. *Blood* 2008; 112(11):Abst. 148.

<http://ash.confex.com/ash/2008/webprogram/Paper11587.html>

Protocol(s): AAML03P1

Pollard JA, Zeng R, Ho PA, Alonzo T, Gerbing R, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin J, Lange B, Meshinchi S: Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML: Report from Children's Oncology Group. *Blood* 2008; 112(11):Abst. 143.

<http://ash.confex.com/ash/2008/webprogram/Paper12412.html>

Protocol(s): CCG-2961, CCG-2941, AAML03P1

Rabin K, Wang J, Tsimelzon A, Morrison D, Gaikwad A, Hogan L, Rye CL, Hilsenbeck SG, Devidas M, Heerema NA, Carroll AJ, Pession A, Basso G, Carroll WL, Bhojwani D: Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome versus Non-Down Syndrome Patients. *Blood* 2008; 112(11):Abst. 1203.

<http://ash.confex.com/ash/2008/webprogram/Paper6333.html>

Protocol(s): Multiple Trials

Robinson B, Cao K, Hilden JM, Dinndorf P, Heerema NA, Sather H, McGlennen R, Hunger S, Reaman GH, Wang L, Felix C: Age Is the Strongest Determinant of Leukemia Blast Cell Gene Expression in MLLRearranged Infant ALL and MLL-AF4 Directs a Distinct Gene Expression Profile Related to CNS Disease. Blood 2008; 112(11):Abst.1200.

<http://ash.confex.com/ash/2008/webprogram/Paper5565.html>

Protocol(s): CCG-1953

Roshal M, Fromm J, Winter SS, Dunsmore KP, Wood BL: T Cell Acute Lymphoblastic Leukemia (T-ALL) Blasts Lose Expression of Markers of Immaturity during Chemotherapy: Implications for the Detection of Minimal Residual Disease. Blood 2008; 112(11):Abst. 1521.

<http://ash.confex.com/ash/2008/webprogram/Paper8641.html>

Protocol(s): AALL0434

Schultz KR, Bowman WP, Slayton WB, Aledo A, Devidas M, Sather H, Borowitz M, Davies SM, Trigg ME, Pasut B, Jorstad DT, Eslinger T, Burden L, Wang C, Rutledge R, Camitta BM, Gaynon PS, Carroll AJ, Heerema NA, Winick N, Hunger S, Carroll WL: Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031. Blood 2008; 112(11):Abst. 911.

<http://ash.confex.com/ash/2008/webprogram/Paper4882.html>

Protocol(s): AALL0031

Yang J, Yang W, Cheng C, Devidas M, Cao X, Campana D, Borowitz M, Willman CL, Bowman WP, Reaman GH, Carroll WL, Hunger S, Evans WE, Pui C, Relling MV: Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood 2008; 112(11):Abst. 14.

<http://ash.confex.com/ash/2008/webprogram/Paper8571.html>

Protocol(s): AALL0031

Zhang A, Robinson B, Cao K, Behling K, Devidas M, Alonzo T, Raimondi SC, Carroll AJ, Arceci R, Gamis A, Hunger S, Reaman GH, Harvey RC, Willman CL, Wang L, Felix C: Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants. Blood 2008; 112(11):Abst. 2255.

<http://ash.confex.com/ash/2008/webprogram/Paper8589.html>

Protocol(s): P9407, POG-8398, POG-8493, POG-8821/22, POG-9107, POG-9421

Zhang A, Robinson B, Wang L, Cao K, Cory L, Barrett JS, Atlas SR, Chen I, Harvey RC, Willman CL, Devidas M, Carroll AJ, Hunger S, Moore J, Thompson CB, Kundu M, Felix C: Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias. Blood 2008; 112(11):Abst. 2647.

<http://ash.confex.com/ash/2008/webprogram/Paper12949.html>

Protocol(s): CCG-2891, AAML03P1, P9407, CCG-1961, CCG-2961

ECOG

Kay NE, Kim HT, Kempin SJ, Secreto C, Knox T, Tschumper R, Jelink O, Smoley S, Van Dyke D, Salzman J, Tallman MS, Rosen ST: Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903. *Blood* 2008; 112(11):Abst. 1057.

<http://ash.confex.com/ash/2008/webprogram/Paper3581.html>

Protocol(s): E2903

Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Allen CC, Gale RE, Buck G, Richards S, Paietta EM, Tallman MS, Goldstone AR, Rowe JM, Ferrando AA, Linch DC: Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol. *Blood* 2008; 112(11):Abst. 2548.

<http://ash.confex.com/ash/2008/webprogram/Paper14776.html>

Protocol(s): INT-0132

Paietta EM, Li H, Richards SM, Racevskis J, Dewald G, Rowe JM, Tallman MS, Lazarus RN, Litzow MR, Goldstone AR, Wiernik PH: Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se. *Blood* 2008; 112(11):Abst. 1500.

<http://ash.confex.com/ash/2008/webprogram/Paper5614.html>

Protocol(s): INT-0132

Paietta EM, Li X, Richards SM, Racevskis J, Dewald G, Rowe JM, Tallman MS, Lazarus HM, Litzow MR, Goldstone M, Wiernik PH: Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial. *Blood* 2008; 112(11):Abst. 1907.

<http://ash.confex.com/ash/2008/webprogram/Paper5270.html>

Protocol(s): INT-0132

Rowe JM, Buck G, Moorman AV, Tallman MS, Richards SM, Fielding AK, Burnett AK, Franklin IM, Wiernik PH, Lazarus HM, Paietta E, Litzow MR, Marks DI, Luger S, Dewald GW, Goldstone AH: Standard Consolidation /Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII / ECOG E2993). *Blood* 2008; 112(11):Abst. 3314.

<http://ash.confex.com/ash/2008/webprogram/Paper4197.html>

Protocol(s): INT-0132

Rowe JM, Sun Z, Cassileth PA, Appelbaum FR, Wiernik PH, Lazarus HM, Blume KG, Fernandez HF, Litzow MR, Tallman MS: Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). *Blood* 2008; 112(11):Abst. 49.

<http://ash.confex.com/ash/2008/webprogram/Paper6600.html>

Protocol(s): INT-0132

Rowe JM, Yao X, Cassileth PA, Appelbaum FR, Wiernik PH, Schiffer C, Litzow MR, Luger S, Bennett JM, Lazarus HM, Tallman MS: The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG). *Blood* 2008; 112(11):Abst. 1952.

<http://ash.confex.com/ash/2008/webprogram/Paper7613.html>

Protocol(s): INT-0132

Lung Cancer

ACRIN

Larke F: Estimated Radiation Dose to Participants Receiving Low-Dose Multi Detector CT Chest Scans in the National Lung Cancer Screening Trial (NLST). Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6654

Lynch D: Baseline Characteristics of National Lung Screening Trial Study Population Presented on behalf of the National Lung Screening Trial investigators. Radiological Society of North America (RSNA), Chicago, Illinois, Nov, 2008.

Protocol(s): ACRIN-6654

Siegel B: Local Institution vs. Central Review Determination of SUV for Stage III Non-small Cell Lung Cancer: Preliminary Analysis of ACRIN 6668/RTOG 0235. American College of Radiology Imaging Network (ACRIN) Fall, Arlington, Virginia, Oct, 2008.

Protocol(s): ACRIN-6668

Werner-Wasik M, Machtay M, Alavi A, Acharya S, Saffer J, Snyder B: Local Institution versus Central Review Determination of SUV for Stage III Non-small Cell Lung Cancer: Preliminary Analysis of ACRIN 6668/RTOG 0235. Radiological Society of North America, Chicago, Illinois, Nov, 2008. Abst. SSC16-03.

http://rsna2008.rsna.org/event_display.cfm?em_id=6011173

Protocol(s): ACRIN-6668

ECOG

Hoang T, Dahlberg SE, Sandler AB, Brahrner JR, Schiller JH, Johnson DR: A Prognostic Model to Predict Survival in Bevacizumab (B) Eligible Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Standard Chemotherapy: ECOG Data. Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, Illinois, Nov, 2008. Abst. 126.

<http://www.oncolymmeetings.org/lung/abstracts.htm>

Protocol(s): E4599

Sandler AB, Kong G, Strickland D, Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Oncology Group (ECOG) Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* 2008; 3(11):Abst. 133.

<http://jto.org/pt/re/jto/pdfhandler.01243894-200811001-00003.pdf;jsessionid=JMwTMW472pp6QGL01WDK2fHc1YH81Dd5sWXnjLiCTFhRmVJN8rybl-1035908147!181195628!8091!-1>

Protocol(s): E4599

Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry M, Langer CJ, Sandler AB, Belani CP, Johnson DH: Increased Benefit from Bevacizumab in Younger Woman with Advanced NSCLC on Eastern Cooperative Oncology Group E4599. *Journal of Thoracic Oncology* 2008; 3(11):Abst. 131
<http://jto.org/pt/re/jto/pdfhandler.01243894-200811001-00003.pdf;jsessionid=JMwTMW472pp6QGL01WDK2fHc1YH81Dd5sWXnjLiCTFhRmVJN8ryb!-1035908147!181195628!8091!-1>
 Protocol(s): E4599

RTOG

Komaki R, Paulus R, Olsen C, Conway P, Ang KK, Trotti A, Blumenschein G, Curran W, Choy H, Hirsch F: Correlation of EGFR Expression by IHC & FISH to Predict Patient Outcome: A Phase II RTOG 0324 Study for Patients With Stage III NSCLC Treated by Chemoradiotherapy & Cetuximab (C225). *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 1006.
[http://www.redjournal.org/article/S0360-3016\(08\)01243-1/fulltext](http://www.redjournal.org/article/S0360-3016(08)01243-1/fulltext)
 Protocol(s): RTOG-0324

Lymphoma and Plasma Cell Disorders

CALGB

Blum KA, Johnson JL, Jung S, Cheson BD, Bartlett NL: Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. *Blood* 2008; 112(11):Abst. 232.
<http://ash.confex.com/ash/2008/webprogram/Paper8356.html>
 Protocol(s): CALGB-50502

Czuczman MS, Leonard JP, Johnson JL, Jung S, Hsi E, Byrd JC, Cheson BD: FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. *Blood* 2008; 112(11):Abst. 1003.
<http://ash.confex.com/ash/2008/webprogram/Paper6795.html>
 Protocol(s): CALGB-50402

Hsi ED, Said J, Johnson JL, Jung S, Lai R, Jones D, Chadburn A, Cheson BD, Wilson WH: Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study. *Blood* 2008; 112(11):Abst. 476.
<http://ash.confex.com/ash/2008/webprogram/Paper7504.html>
 Protocol(s): CALGB-50103

Kostakoglu L, Straus DJ, Schöder H, LaCasce AS, Bartlett NL, Nathan Hall N, Johnson JL, Jung S, Canellos GP, Schwartz LH, Cheson BD: Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.. *Blood* 2008; 112(11):Abst. 1460.
<http://ash.confex.com/ash/2008/webprogram/Paper12151.html>
 Protocol(s): CALGB-50203

COG

Abromowitch M, Termuhlen A, Chang M, Perkins S, Gross TG, Weinstein H, Finlay J: High-dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized arms of COG A5971. *Blood* 2008; 112(11):Abst. 3610.

<http://ash.confex.com/ash/2008/webprogram/Paper9909.html>

Protocol(s): A5971

Cairo M, Lynch J, Harrison L, van de Ven C, Gross TG, Shiramizu B, Sanger W, Perkins S, Goldman SC: Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. *Blood* 2008; 112(11):Abst. 838.

<http://ash.confex.com/ash/2008/webprogram/Paper6502.html>

Protocol(s): ANHL01P1

Cairo M, Sposto R, Gerrard M, Waxman I, Goldman SC, Harrison L, Auperin A, Pinkerton R, Perkins S, Raphael M, McCarthy K, Patte C: Tumor Histology, Advanced Stage, and Primary Site, Explain the Increased Risk of Failure in Adolescents (age ≥ 15) with Newly Diagnosed B-NHL: Results of the FAB/LMB 96. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. O.149.

Protocol(s): CCG-5961

Wolden S: Hodgkin's Disease: What the children have taught adults. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. S.060.

Protocol(s): AHOD0031

ECOG

Dispenzieri A, Jacohus SJ, Vesole DH, Rajkumar SV, Greipp PR: Primary Therapy with Bortezomib the role of induction, maintenance, and re-induction in patients with high risk myeloma. *Blood* 2008; 112(11):Abst. 1738.

<http://ash.confex.com/ash/2008/webprogram/Paper8715.html>

Protocol(s): E2A02

Horning SJ, Juweid M, Schoder H, Wiseman G, Mcmillan A, Swinrien U, Advani R, Gascoyne RU, Quon A: Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of E3404. *Blood* 2008; 112(11):Abst. 372.

<http://ash.confex.com/ash/2008/webprogram/Paper11041.html>

Protocol(s): E3404

Jacobus SJ, Kumar SK, Callander NS, Ahonour R, Fonseca R, Siegel OS, Greipp PR, Rajkumar SV: Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occuring in E4A03 Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RU) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). *Blood* 2008; 112(11):Abst. 1740.

<http://ash.confex.com/ash/2008/webprogram/Paper15456.html>

Protocol(s): E4A03

Kumar SK, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M, Blood EA, DeGoey R, Henderson K, Bradwell A, Kyle PA, Greipp PR, Rajkumar SV, Fonseca B: Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications. *Blood* 2008; 112(11):Abst. 1677.

<http://ash.confex.com/ash/2008/webprogram/Paper14537.html>

Protocol(s): EST-9486

SWOG

Deffenbacher KE, Wright G, Iqbal J, Geng H, O'Shea D, Lister A, Fitzgibbon J, Zhongfenh L, Weisenburger D, Greiner TC, Gascoyne RD, Rosenwald A, Campo E, Rimsza LM, Delabie J, Jaffe ES, Staudt LM, Chan WC: Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. *Blood* 2008; 112(11):Abst. 2049.

<http://ash.confex.com/ash/2008/webprogram/Paper7316.html>

Protocol(s): SWOG-8819

Hsi ED, Goldman B, Rimsza LM, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Sweetenham JW: MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study. *Blood* 2008; 112(11):Abst. 376.

<http://ash.confex.com/ash/2008/webprogram/Paper5296.html>

Protocol(s): S8809-S9800, S9800, S9911, SWOG-8809

Lenz G, Wright G, Dave SS, Xiao W, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, et al.: Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. *Blood* 2008; 112(11):Abst. 475.

<http://ash.confex.com/ash/2008/webprogram/Paper3834.html>

Protocol(s): SWOG-8819

Miller TP, Unger JM, Spier CM, Stea B, Press O, LeBlanc M, Fisher RI: Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313). *Blood* 2008; 112(11):Abst. 3598.

<http://ash.confex.com/ash/2008/webprogram/Paper4856.html>

Protocol(s): S0313

Schaefer-Cuttillo J, Chengazi V, Peterson D, Maloney D, Kibler K, Cebula E, Bernstein S, Young F, Press O, Rimsza L, Fisher R, Friedberg J: Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin's Lymphoma (NHL): Analysis of SWOG Clinical Trials. *Blood* 2008; 112(11):Abst. 2000.

<http://ash.confex.com/ash/2008/webprogram/Paper4478.html>

Protocol(s): S0433, S0016

Other Participating Group(s): CALGB

Sarcoma/Bone and Soft Tissue Cancers

COG

Bielack S, Sydes M, Butterfass-Bahloul T, Calaminus G, Carrle D, Marina N, Morgan R, Oellers A, Smeland S, Tomiczek M, Whelan J, Bernstein M: Overcoming Hurdles to Patient Oriented Clinical Research: Successful Multinational Cooperation in the European and American Osteosarcoma Study (EURAMOS). International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. O.127.

Protocol(s): Multiple Trials

Chou AJ, Kleinerman E, Krailo M, Chen Z, Betcher DL, Healey J, Conrad EU, Nadel H, Nieder M, Sato J, Weiner M, Wells RJ, Womer R, Meyers P: Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly Diagnosed Metastatic Osteosarcoma: A Report from the Children's Oncology Group. Connective Tissue Oncology Society, London, United Kingdom, Nov, 2008. Abst. 234942.

Protocol(s): INT-0133

RTOG

Chow E, James J, Barsevick AM, Hartsell W, Scarantino C, Ivker R, Roach III M, Suh J, Petersen I, Bruner D: Functional Interference Clusters in Cancer Patients with Bone Metastases: An Analysis of RTOG 9714. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 1062.

[http://www.redjournal.org/article/S0360-3016\(08\)01300-X/fulltext](http://www.redjournal.org/article/S0360-3016(08)01300-X/fulltext)

Protocol(s): RTOG-97-14

Other Participating Group(s): NCCTG

Other Cancer

COG

Ayello J, Berg S, Krailo M, van de Ven C, Lewis D, Harrison L, Blaney S, Adamson P, Cairo M: Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. *Blood* 2008; 112(11):Abst. 107.

<http://ash.confex.com/ash/2008/webprogram/Paper8028.html>

Protocol(s): ADVL0319

Elkin TD, Megason GC, Forsythe A, Breland T, Johnson DP, Rhea J: Behavioral and Medical Effects of Marital Status of Caregivers on Children with Cancer. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. K007.

Protocol(s): Multiple Trials

Gumy-Pause F, Ozsahin HA, Khoshbeen-Boudal M, Betts D, Maillet P, Sappino A: Detection of ATM Gene Deletions/Duplication by Multiplex Ligation-Dependant Probe Amplification (MLPA) in Childhood Lymphoid Malignancies: A Report from the Children's Oncology Group. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. O.082.

Protocol(s): Multiple Trials

Luer S, Berger S, Ammann RA, Diepold M, Duppenhaler A, Leibundgut KE, A, von Gunten M, Aebi C: Successful Treatment of Intestinal and Hepatic Zygomycosis in an Immunocompromised Child. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. G006.
Protocol(s): AALL0331

Luer S, Hirt A, Zimmermann A, Gill A, Salman EK, Monteleone PM, French CA: Treatment of Nut Midline Carcinoma (NMC) in children and young adults. A Case Series and call for networking. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. O.125.
Protocol(s): Multiple Trials

Olson TA, Krailo M, Malogolowkin M, Marina N, Rodriguez-Galindo C, Rescorla F, Frazier AL: Overview of Treatment Results: Children's Oncology Group High Risk Germ Cell Tumor Protocols. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. S.032.
Protocol(s): P9749

Olson TA, Krailo M, Rodriguez-Galindo C, Malogolowkin M, Rescorla F, Billmire DF, Frazier AL: Increased Risk for Recurrence for Older Adolescents with Malignant Germ Cell tumors. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. S007.
Protocol(s): INT-0097, INT-0106

Wall D, Schultz KR, Reaman GH, Khayat AF, Woelkers J, Levine J, Gamis A: Successful Test of Interoperability of the Established Children's Oncology Group Clinical Trial Infrastructure: Results of the COG-PBMTC Collaboration. International Society of Pediatric Oncology (SIOP), Berlin, Germany, Oct, 2008. Abst. F003.
Protocol(s): ASCT0431, ASCT0521, ASCT0631

RTOG

Bruner DW, Gotay C, Moinpour C, Atherton P, Johnson V, Winter K, Schaefer P, Movsas B, Sloan J: Value-Added of Patient-Reported Outcomes (PRO) in Cooperative Group Oncology Clinical Trials: A Pooled Analysis. International Society for Quality of Life Research (ISOQOL), Montevideo, Uruguay, Oct, 2008. Abst. 1631.
http://www.isoqol.org/2008_conference/AbstractsForBooklet_2008v3.pdf
Protocol(s): Multiple Trials

Straube WL, Bosch WR, Matthews JW, Michalski JM, O'Meara E, Purdy JA: Impact of Protocol Complexity on Digital Data Integrity Quality Assurance for Clinical Trials Requiring Digital Data Submission. *Int J Radiat Oncol Biol Phys* 2008; 72(Suppl):Abst. 3109.
[http://www.redjournal.org/article/S0360-3016\(08\)02336-5/fulltext](http://www.redjournal.org/article/S0360-3016(08)02336-5/fulltext)
Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Freyer DR, Seibel N, La MK, Devidas M, Carroll WL, Hunger S, Gaynon PS: Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents is Independent of Prior Treatment Intensity: A Report from the Children's Oncology Group (COG). *Blood* 2008; 112(11):Abst. 917.

<http://ash.confex.com/ash/2008/webprogram/Paper13841.html>

Houghton PJ, Morton CL, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang MH, Smith MA: Pediatric Preclinical Testing Program (PPTP) Evaluation of Rapamycin Combined with Cytotoxic Drugs Used Frequently in Treatment of Childhood Cancer. *European Journal of Cancer* 2008; 6(12):Abst. 190.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-74-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=7dbc44c316bcf89b45c315d2bc95c0b3&ie=/sdarticle.pdf

Kolb EA, Morton C, Houghton PJ, Maris JM, Friedman HS, Keir ST, Gorlick RG, Kang MH, Reynolds CP, Smith MA: Pediatric Preclinical Testing Program (PPTP) Evaluation of the Fully Human Anti-IGF-1R Antibody IMC-A12. *European Journal of Cancer* 2008; 6(12):Abst. 558.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-PB-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=30005a22c5ecab641661684254a9452a&ie=/sdarticle.pdf

Lock R, Carol H, Houghton P, Morton C, Phelps D, Tucker C, Payne-Turner D, Zuany-Amorim C, Smith M: Pediatric Preclinical Testing Program (PPTP) Avaluation of the Anti-CD19-DM4 Conjugated Antibody SAR3419. *European Journal of Cancer* 2008; 6(12):Abst. 192.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-76-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=769d58b1d88574e7cbf7b4173836fefd&ie=/sdarticle.pdf

Morton CL, Houghton PJ, Maris JM, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Smith MA: Pediatric Preclinical Testing Program (PPTP) Evaluation of the Oncolytic Picornavirus, NTX-010 (SVV-001). *European Journal of Cancer* 2008; 6(12):Abst. 191.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-75-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=e1f30cce3b84d8792b36680d3f7f857e&ie=/sdarticle.pdf

O'Mara AM, Denicoff A, Reeve B, Trimble T: An Analysis of Quality of Life Endpoints and Measures in National Cancer Institute-Sponsored Cancer Treatment Trials. *International Society for Quality of Life Research (ISOQOL), Montevideo, Uruguay, Oct, 2008. Abst. 69/1739.*

http://www.isoqol.org/2008_conference/AbstractsForBooklet_2008v3.pdf

Smith MA, Houghton PJ, Morton CL, Maris JM, Courtright J, Carol H, Lock RB, Yang Y, Manfredi MG: Pediatric Preclinical Testing Program (PPTP) Stage 2 Testing of the Aurora A Kinase Inhibitor MLN8237. *European Journal of Cancer* 2008; 6(12):Abst. 286.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-BM-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=f05ae5f0b2b7d1848499cedfcacec9bf&ie=/sdarticle.pdf

Activities with DCTD and DCP Investigators

Mooney, M: Planning Committee Member: NCI Clinical Trials Planning Meeting in Hepatocellular Cancer. NCI Gastrointestinal Malignancies Steering Committee, Washington, DC, Dec, 2008.

Mooney, M: AASLD/NCI NIH Corner, Hepatocellular Carcinoma: Etiology, Prevention and Treatment. American Association for the Study of Liver Diseases, San Francisco, California, Nov, 2008.

Seibel N, Chen H: Discuss IGF-1R Targeted Therapies for Ewing Sarcoma. COG, SARC, and CTEP Meeting, Rockville, Maryland, Nov, 2008.

Seibel, N: Acute lymphoblastic leukemia: an historical perspective, Hematology Am Soc Hematol Educ Program. American Society of Hematology, San Francisco, California, Dec, 2008: Pg 365.

Seibel, N: Meet the Expert Session, Acute Lymphoblastic Leukemia in children and adolescents. Hematology Am Soc Hematology Educ Program. American Society of Hematology, San Francisco, California, Dec, 2008.

Seibel, N: Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls. Hematology Am Soc Hematol Educ Program. American Society of Hematology, San Francisco, California, Dec, 2008: Pgs 374-380.

Zujewski JA: Patterns of Care for Male Breast Cancer. Male Breast Cancer: A Multidisciplinary Scientific Update Meeting, Rockville, Maryland, Sep, 2008.

Disclaimer: *References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.*